))
Risk of eye damage in patients with SLE and RA taking hydroxychloroquine
Manage episode 446536568 series 3610272
Sisällön tarjoaa Arthritis Consumer Experts. Arthritis Consumer Experts tai sen podcast-alustan kumppani lataa ja toimittaa kaiken podcast-sisällön, mukaan lukien jaksot, grafiikat ja podcast-kuvaukset. Jos uskot jonkun käyttävän tekijänoikeudella suojattua teostasi ilman lupaasi, voit seurata tässä https://fi.player.fm/legal kuvattua prosessia.
In this episode of Arthritis At Home, Cheryl Koehn, Founder and President at Arthritis Consumer Experts, speaks to Dr. J. Antonio Aviña-Zubieta, UBC Division Head of Rheumatology, BC Lupus Society Research Scholar, and Senior Scientist at Arthritis Research Canada. They discuss the INTACT study, an ongoing study working to determine the risk of eye damage in people with systemic lupus erythematosus and rheumatoid arthritis who are taking hydroxychloroquine.
If you are interested in participating in this study, please ask your rheumatologist to refer you for an annual retina screening test as part of the INTACT study during your upcoming visit. To learn more about the study, please email the team at [email protected]
Additional learning resources
- Current Research: Risk of Retinal Toxicity in Patients with Systemic Lupus Erythematosus and Rheumatoid Arthritis on Long-term Hydroxychloroquine Therapy
- Learn more about hydroxychloroquine therapy in SLE and RA
- Learn more about lupus at Arthritis Consumer Experts’ About Lupus page
- Learn more about rheumatoid arthritis at Arthritis Consumer Experts’ About Rheumatoid Arthritis page
130 jaksoa
Jaa
